放化疗后食管癌心脏与肺剂量是总生存的独立预测因素
本研究分析2004至2016年接受调强放疗(中位剂量50.4 Gy)同步放化疗±手术的560例食管癌患者,中位随访29.3个月,5年总生存(OS)率41.7%。心脏V30>45%和平均肺剂量(MLD)>10 Gy经多因素校正后与更差生存独立相关(P<0.05),且两者也是放射性心脏和肺并发症的危险因素。
要点
- 心脏V30>45%与MLD>10 Gy是食管癌放化疗后总生存的独立不良预测因素。
- 心脏V30>45%者心脏并发症发生率15% vs 8.5%(P=0.046)。
- MLD>10 Gy者肺部并发症发生率27% vs 18.8%(P=0.020)。
核心结论
- 心脏和肺受照剂量均独立预测食管癌患者更差的总生存,且是放射性并发症的危险因素,应整体最小化心脏和肺剂量。
研究设计与样本
- 回顾性分析2004至2016年接受调强放疗(中位剂量50.4 Gy)同步放化疗±手术的560例食管癌患者,中位随访29.3个月。
主要发现
- 全组5年总生存率为41.7%。
- 心脏V30>45%和平均肺剂量(MLD)>10 Gy经其他临床和剂量学因素校正后与更差生存独立相关(P<0.05)。
- 心脏V30≤45%者心脏并发症发生率8.5%,V30>45%者为15%(P=0.046)。
- MLD≤10 Gy者肺部并发症发生率18.8%,MLD>10 Gy者为27%(P=0.020)。
- 发生心脏并发症者5年OS率27.6% vs 无并发症者43.2%(P=0.012);发生肺部并发症者5年OS率23.1% vs 无并发症者47.4%(P<0.001)。
关键数值与推荐
- 心脏V30>45%和MLD>10 Gy为与更差生存独立相关的剂量学阈值(采用Contal和O'Quigley法确定)。
临床怎么用
- 食管癌同步放化疗放疗计划设计时,应尽可能降低心脏V30和平均肺剂量,以改善生存并减少放射性心脏和肺并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze associations between heart and lung dose and overall survival (OS) in patients with esophageal cancer who received concurrent chemo-radiotherapy (CCRT) with or without surgery. PATIENTS AND METHODS: Patients received intensity-modulated radiation therapy (median dose 50.4 Gy) from 2004 through 2016. Cutoff points for continuous variables were calculated using the method of Contal and O'Quigley. Kaplan-Meier method with log-rank tests was used to calculate survival. OS was analyzed with both univariate and multivariable Cox models. RESULTS: In all, 560 patients were analyzed; median follow-up time was 29.3 months, and 5-year OS rate was 41.7%. Heart V30 >45% and mean lung dose (MLD) >10 Gy were found to be independently associated with worse survival after adjustment for other clinical and dosimetric factors (P < 0.05). Heart and lung doses were also found to be risk factors for radiation-induced cardiac and pulmonary complications (P < 0.05): 8.5% of patients with heart V30 ≤45% had cardiac complications vs. 15% for V30 >45% (P = 0.046); 18.8% of patients with MLD ≤10 Gy had pulmonary complications vs. 27% for MLD >10 Gy (P = 0.020). Having cardiac complications was associated with worse survival (5-year OS rates 27.6% with vs. 43.2% without, P = 0.012), and having pulmonary complications was associated with worse survival as well (5-year OS rates 23.1% with vs. 47.4% without, P < 0.001). CONCLUSION: Both heart and lung doses independently predicted worse OS in patients with esophageal cancer, even after adjustment for other clinical and dosimetric factors, and were also risk factors for radiation-induced complications. Both irradiated heart and lung doses should be minimized as a whole.
引用
- Xu C, Guo L, Liao Z, et al. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol. 2019. PMID: 31080898. doi:10.1016/j.ctro.2019.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。